Nicoxamat (Synonyms: N-Hydroxynicotinamide) |
Catalog No.GC78873
One-Click Copy Product Info
|
Nicoxamat (N-Hydroxynicotinamide) is a HCV inhibitor as well as a selective HDAC6 inhibitor.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 5657-61-4
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
In Vitro, Nicoxamat (compound IIa) inhibits the proliferation of HCV full-length genomic replicons in Huh7 luc/neo cells, with an EC50 of 25 μM, a CC50 of 450 μM, and a selectivity index of 18[1]. Nicoxamat (20-100 μM) induces concentration-dependent hyperacetylation of α-tubulin in Huh7-luc/neo cells[1]. Nicoxamat (100 μM; 72 h) does not induce significant histone H3 acetylation in Huh7-luc/neo cells, indicating its selectivity for class I HDACs[1]. Nicoxamat (0-100 μM) exhibits concentration-dependent inhibition of HCV replicon and HDAC6 inhibitory activity in Huh7-luc/neo cells, with its HCV inhibitory activity being stronger than HDAC6 inhibitory activity at low concentrations[1].
References:
[1]. Kozlov MV, et al. Pyridine hydroxamic acids are specific anti-HCV agents affecting HDAC6. Bioorg Med Chem Lett. 2015;25(11):2382-2385.
| Cas No. | 5657-61-4 | SDF | |
| Synonyms | N-Hydroxynicotinamide | ||
| Formula | C6H6N2O2 | M.Wt | 138.13 |
| Solubility | DMSO: 25 mg/mL (180.99 mM; Need ultrasonic) | Storage | Store at -20°C |
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 7.2396 mL | 36.1978 mL | 72.3956 mL |
| 5 mM | 1.4479 mL | 7.2396 mL | 14.4791 mL |
| 10 mM | 724 μL | 3.6198 mL | 7.2396 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)